Orapem NDA Is Replidyne’s First
This article was originally published in The Pink Sheet Daily
Executive Summary
Replidyne has submitted an NDA for its antibiotic Orapem (faropenem medoxomil)
You may also be interested in...
Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.
Forest’s Faropenem Is “Not Approvable”; Additional Studies Will Take Two Years
FDA decision reflects the agency's new position on the need for superiority studies to support the approval of antibiotics, Replidyne says.
Forest Enters Antibiotic Field Through Faropenem Licensing Deal
Forest will oversee U.S. sales and marketing efforts for the pending antibiotic Orapem under an agreement with Replidyne.